180 related articles for article (PubMed ID: 34825941)
1. Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
Yoshida K; Fujita A; Narazaki H; Asano T; Itoh Y
Cancer Chemother Pharmacol; 2022 Jan; 89(1):83-91. PubMed ID: 34825941
[TBL] [Abstract][Full Text] [Related]
2. Melatonin overcomes resistance to clofarabine in two leukemic cell lines by increased expression of deoxycytidine kinase.
Yamanishi M; Narazaki H; Asano T
Exp Hematol; 2015 Mar; 43(3):207-14. PubMed ID: 25461250
[TBL] [Abstract][Full Text] [Related]
3. p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.
Davies C; Hogarth LA; Dietrich PA; Bachmann PS; Mackenzie KL; Hall AG; Lock RB
J Biol Chem; 2011 Oct; 286(43):37639-50. PubMed ID: 21903579
[TBL] [Abstract][Full Text] [Related]
4. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine.
Rothenburger T; McLaughlin KM; Herold T; Schneider C; Oellerich T; Rothweiler F; Feber A; Fenton TR; Wass MN; Keppler OT; Michaelis M; Cinatl J
Commun Biol; 2020 Jun; 3(1):324. PubMed ID: 32581304
[TBL] [Abstract][Full Text] [Related]
5. Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.
Huang M; Inukai T; Miyake K; Tanaka Y; Kagami K; Abe M; Goto H; Minegishi M; Iwamoto S; Sugihara E; Watanabe A; Somazu S; Shinohara T; Oshiro H; Akahane K; Goi K; Sugita K
Cancer Med; 2018 Apr; 7(4):1297-1316. PubMed ID: 29473342
[TBL] [Abstract][Full Text] [Related]
6. High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia.
Akahane K; Murakami Y; Kagami K; Abe M; Harama D; Shinohara T; Watanabe A; Goi K; Nishi R; Yamauchi T; Kimura S; Takita J; Look AT; Minegishi M; Sugita K; Inukai T
Hematol Oncol; 2019 Oct; 37(4):516-519. PubMed ID: 31335977
[No Abstract] [Full Text] [Related]
7. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
Månsson E; Flordal E; Liliemark J; Spasokoukotskaja T; Elford H; Lagercrantz S; Eriksson S; Albertioni F
Biochem Pharmacol; 2003 Jan; 65(2):237-47. PubMed ID: 12504799
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.
Kuang SQ; Fang Z; Zweidler-McKay PA; Yang H; Wei Y; Gonzalez-Cervantes EA; Boumber Y; Garcia-Manero G
PLoS One; 2013; 8(4):e61807. PubMed ID: 23637910
[TBL] [Abstract][Full Text] [Related]
9. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
Homminga I; Zwaan CM; Manz CY; Parker C; Bantia S; Smits WK; Higginbotham F; Pieters R; Meijerink JP
Blood; 2011 Aug; 118(8):2184-90. PubMed ID: 21730354
[TBL] [Abstract][Full Text] [Related]
10. Analysis of DNA methylation of the 5' region of the deoxycytidine kinase gene in CCRF-CEM-sensitive and cladribine (CdA)- and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (CAFdA)-resistant cells.
Leegwater PA; De Abreu RA; Albertioni F
Cancer Lett; 1998 Aug; 130(1-2):169-73. PubMed ID: 9751270
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.
Freiburghaus C; Emruli VK; Johansson A; Eskelund CW; Grønbæk K; Olsson R; Ek F; Jerkeman M; Ek S
BMC Cancer; 2018 Apr; 18(1):466. PubMed ID: 29695239
[TBL] [Abstract][Full Text] [Related]
12. Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.
Sripornsawan P; Okamoto Y; Nishikawa T; Kodama Y; Yamaki Y; Kurauchi K; Tanabe T; Nakagawa S; Shinkoda Y; Imuta N; Kawano Y
Pediatr Blood Cancer; 2017 Feb; 64(2):250-253. PubMed ID: 27576612
[TBL] [Abstract][Full Text] [Related]
13. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.
Lotfi K; Månsson E; Spasokoukotskaja T; Pettersson B; Liliemark J; Peterson C; Eriksson S; Albertioni F
Clin Cancer Res; 1999 Sep; 5(9):2438-44. PubMed ID: 10499616
[TBL] [Abstract][Full Text] [Related]
14. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients.
Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
Vet J; 2014 Jan; 199(1):103-9. PubMed ID: 24332606
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
Bachmann PS; Piazza RG; Janes ME; Wong NC; Davies C; Mogavero A; Bhadri VA; Szymanska B; Geninson G; Magistroni V; Cazzaniga G; Biondi A; Miranda-Saavedra D; Göttgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-Passerini C; Pimanda JE; Lock RB
Blood; 2010 Oct; 116(16):3013-22. PubMed ID: 20647567
[TBL] [Abstract][Full Text] [Related]
17. Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.
Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
BMC Cancer; 2014 Jul; 14():547. PubMed ID: 25070259
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
Kitange GJ; Mladek AC; Carlson BL; Schroeder MA; Pokorny JL; Cen L; Decker PA; Wu W; Lomberk GA; Gupta SK; Urrutia RA; Sarkaria JN
Clin Cancer Res; 2012 Aug; 18(15):4070-9. PubMed ID: 22675172
[TBL] [Abstract][Full Text] [Related]
19. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]